Development of new antituberculosis drugs: Its relevance worldwide and in the Asia–Pacific region
Open Access
- 18 August 2008
- journal article
- Published by Wiley in Respirology
- Vol. 13 (s3) , S125-S131
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Advances in the Treatment of TuberculosisClinical Pharmacology & Therapeutics, 2007
- New Tuberculosis Therapeutics: A Growing PipelineThe Journal of Infectious Diseases, 2007
- After decades of drought, new drug possibilities flood TB pipelineNature Medicine, 2007
- Aspirin and ibuprofen enhance pyrazinamide treatment of murine tuberculosisJournal of Antimicrobial Chemotherapy, 2006
- Prospects for Advancing Tuberculosis Control Efforts through Novel TherapiesPLOS Medicine, 2006
- Outpatient Gatifloxacin Therapy and Dysglycemia in Older AdultsNew England Journal of Medicine, 2006
- Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2004
- Gatifloxacin and Ethionamide as the Foundation for Therapy of TuberculosisAntimicrobial Agents and Chemotherapy, 2003
- Bactericidal Activity of Increasing Daily and Weekly Doses of Moxifloxacin in Murine TuberculosisAntimicrobial Agents and Chemotherapy, 2002
- The action of antituberculosis drugs in short-course chemotherapyTubercle, 1985